SDPA Summer | Live Blog | Product Theater: A Non-Steroid Approach to Treating Atopic Dermatitis
Sponsored by Valeant Pharmaceuticals North America, LLC
During today’s lunchtime lecture at the SDPA’s Annual Summer Dermatology Conference in San Diego, California, Dr. Elizabeth Swanson, a pediatric Dermatologist, reviewed atopic dermatitis (AD) with a focus on the role of Elidel®(pimecrolimus) Cream 1% in the treatment of these patients. AD can be highly visible and troublesome for patients with itching being their most common complaint. The skin barrier in atopic patients is impaired and Elidel® can improve their skin’s barrier function as well as suppress the inflammatory mediators in the skin. She stressed that it is important to educate patients that “there is no cure for eczema” but proper treatment can minimize flares, severity of flares, and time between the flares.
Dr. Swanson explained that Elidel®, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older. It is for patients who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. She highlighted studies showing symptomatic improvement as early as one week of treatment with Elidel® in patients with head and neck AD. Furthermore, the majority of patients with AD were found to have no or mild itching after 8 days of treatment.
Lastly, there is a great deal of safety data on Elidel® as the company has the largest and longest prospective longitudinal study on a dermatological illness. Important to note is that there have been NO reports of skin cancer. The most common adverse events with Elidel® is application site burning, headache and cough.
Byline: Sarah Patton, PA-C, MSHS
Posted: June 3, 2017